Veradermics, Regulatory Wednesday, July 15, 2026 +0.50 Positive

Veradermics Reports Positive Phase 2 Results for Oral Hair Loss Drug

Veradermics announced positive Phase 2 study results for VDPHL01 in female hair loss. The data positions the drug as a potential first FDA-approved oral treatment for this indication.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day